SCHEMBL1018964

SCHEMBL1018964

CCNC(=O)C1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.64
GNAO1 P09471 1/20 0.64
GNAI1 P63096 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.50
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
GABRA1 P14867 1/20 0.48
TSHR P16473 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
GABRA4 P48169 1/20 0.48
GABRE P78334 1/20 0.48
PMP22 Q01453 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6803030 0.98 GNAI3 (0.67) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL8421540 0.98 GNAI3 (0.67) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
SCHEMBL3935665 0.88 GNAI3 (0.51) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
SCHEMBL12574191 0.88 GNAI3 (0.51) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
SCHEMBL1678458 0.86
Hydrochloric Acid SCHEMBL2015546 0.86 GNAI3 (0.54) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
SCHEMBL1438745 0.86 GNAI3 (0.73) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL2015550 0.86 GNAI3 (0.54) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28988641 0.84
SCHEMBL25045022 0.83 GNAI3 (0.55) GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057964-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP claimed
WO-2015057659-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO claimed
US-20040063701-A1 Piperidine derivatives and anti-platelet agents containing the same AJINOMOTO CO., INC (JP) 2004-04-01 US claimed
US-20020147195-A1 Piperidine derivatives and anti-platelet agents containing the same AJINOMOTO CO., INC. (JP) 2002-10-10 US claimed
US-20020019533-A1 PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME MAKINO SHINGO (JP) 2002-02-14 US claimed
EP-0682015-B1 Piperidine derivates and anti-platelet agents containing the same AJINOMOTO KK (JP) 2001-08-22 EP claimed
CN-118146234-A 6,5,7,6-Tetracyclic derivatives, preparation method and application thereof 浙江我武翼方药业有限公司 2024-06-07 CN disclosed
EP-3873600-B9 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2024-02-14 EP disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
EP-3873599-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-27 EP disclosed
EP-3873600-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-20 EP disclosed
CN-110105346-B Optionally substituted quinoline compounds 卫材R&D管理有限公司 2023-03-10 CN disclosed
WO-2023018648-A1 PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM GENENTECH, INC. (US) 2023-02-16 WO disclosed
US-20020037906-A1 Therapeutic agent for intermittent claudication AJINOMOTO CO., INC. (JP) 2002-03-28 US disclosed
EP-1155693-A1 INTERMITTENT CLAUDICATION REMEDIES Ajinomoto Co., Inc. (JP) 2001-11-21 EP disclosed
EP-1155693-A1 INTERMITTENT CLAUDICATION REMEDIES Ajinomoto Co., Inc. (JP) 2001-11-21 EP disclosed
US-6262076-B1 PIPERIDINE DERIVATIVES, E.G., 1-FORMYL-N-(2-(4-(5H-DIBENZO(A, D)CYCLOHEPTENE-5-YLIDEN)-1-PIPERIDINYL))ETHYLISONIPECOTAMIDE AJINOMOTO CO., INC. (JP) 2001-07-17 US disclosed
US-5932593-A ANTISEROTONIN AGENT AJINOMOTO CO., LTD. (JP) 1999-08-03 US disclosed
EP-0168812-A1 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1986-01-22 EP disclosed
US-4560692-A ANTICONVULSANTS OR ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1985-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 GNAI3 483/4885GNAO1 240/4885GNAI1 214/4885
US-20020019533-A1 PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME HTR2A, PDGFRA, PDGFRB GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885
US-20020147195-A1 Piperidine derivatives and anti-platelet agents containing the same HTR2A, PDGFRA, PDGFRB GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885
US-20020037906-A1 Therapeutic agent for intermittent claudication PPIP5K2, QDPR, DLD GNAI3 1022/4885GNAO1 759/4885GNAI1 515/4885
US-20040063701-A1 Piperidine derivatives and anti-platelet agents containing the same HTR2A, PDGFRA, PDGFRB GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.